



Figure A2. Survival of patients with glioblastoma, IDH-wildtype with respect to treatment regimen.


A: Overall survival: concurrent temozolomide vs. no concurrent temozolomide.




B: Overall survival: adjuvant temozolomide vs. no adjuvant temozolomide.




C: Overall survival: radiotherapy alone vs. radiotherapy with both concurrent and adjuvant temozolomide.



D: Progression-free survival: concurrent temozolomide vs. no concurrent temozolomide.



E: Progression-free survival: adjuvant temozolomide vs. no adjuvant temozolomide.



F: Progression-free survival: radiotherapy alone vs. radiotherapy with both concurrent and adjuvant temozolomide.

